Targeting CXCL8 and its receptors could reduce neutrophil-driven inflammation and subsequent tissue damage in IDD. This approach could be particularly effective in the early stages of inflammation.Targeting specific cytokines and transcription factors involved in T cell differentiation (STAT3, FOXP3) could enhance therapeutic outcomes. The gene discussed is FOXP3; the disease is intervertebral disk degenerative disorder.